

Blue Advantage and GLP-1 Agonist Documentation

Blue Advantage continuously monitors our pharmacy prior authorization processes to ensure compliance with CMS Part D requirements. As a result, we will be updating how we perform our prior authorization reviews for GLP-1 Agonists.

We will continue to provide coverage of GLP-1 Agonists in accordance with our formulary for all U.S. Food and Drug Administration-approved and Part D eligible conditions. While there are no changes to the coverage criteria for these products, starting Oct. 1, 2025, we may require documentation be provided in order to decision prior authorization requests. Thank you for your understanding and support in our efforts to ensure our compliance with CMS guidelines.